Arvinas Inc

ARVNNASDAQ · USD
6.46USD-0.28 (-4.16%)
955

Arvinas Inc (ARVN) Covered Calls

Arvinas Inc trades in the Biotechnology industry with an IV Rank of 98.81%, high versus the past year. ARVN's highest covered call setup is the $10.00 strike expiring Apr 16, 2027, sorted by theoretical annualized return. It's 48.37% out of the money with 148 days to expiration, a 49.11% return until expiration, and a 121.12% theoretical annualized return. Across the setups shown, annualized returns run from 18.47% to 121.12% at strikes between $7.00 and $15.00, with 148 to 428 days to expiration, as of Nov 19, 2026.

Read more

Running ARVN covered calls helps you generate income from Arvinas Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ARVN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ARVN stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ARVN covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ARVN covered call is worth writing.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

2027-04-1614810.0048.370.051.25331.0049.11121.12-0.74+0.34231.20
2028-01-2142815.00122.550.353.00861.00127.74108.94-5.19+0.483342.65
2028-01-2142810.0048.370.205.00346.0051.3443.78-2.97+0.64194.80
2028-01-214287.003.861.205.00146.0021.6618.47-17.80+0.733033.80

As of Nov 19, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank98.81% High
  • Market cap (M$)441
  • 52 weeks high-53.55%
  • 52 weeks low6.48%
  • Analyst recommendationBuy
    2.13
  • Target price$14.00
    116.72% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-03
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.18
  • EPS growth next 5 years—

As of Nov 19, 2026